RxDoctor Payments Data

Omar Gonzalez-Camarena, MD

Internal Medicine · El Paso, TXNPI 1780682260

Payments from drug & device makers

$4,848in general payments, 2019–2025

Across 99 payments — averaging $48.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$3K
  • AstraZeneca$402
  • Organogenesis Inc.$200
  • AbbVie$188
  • Lilly USA, LLC$108
  • Bayer$90
  • plus $788 from 19 others

What the payments were for

  • Food & beverage$1,84838%
  • Gifts$3,00062%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,848 in reported general payments places this provider in the 85th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$244,171
Medicare patients
94
Services billed
1,621

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide173$309,137
JanuviaSitagliptin Phosphate134$196,094
OzempicSemaglutide67$110,071
TrulicityDulaglutide25$50,273
FarxigaDapagliflozin Propanediol43$43,258
LinzessLinaclotide39$37,314
EliquisApixaban37$36,820
JardianceEmpagliflozin24$28,995
RybelsusSemaglutide11$27,350
Omega-3 Acid Ethyl Esters142$22,203
VascepaIcosapent Ethyl29$22,076
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog13$21,905
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$15,629
SantylCollagenase Clostridium Hist.20$14,272
JanumetSitagliptin Phos/Metformin Hcl13$13,216

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$108$359,410198 claims
Novo NordiskOzempic, Rybelsus$82$137,42178 claims
AstraZenecaFarxiga, Breztri Aerosphere$402$58,88755 claims
AbbVieLinzess, Synthroid$188$39,66457 claims
Smith+NephewSantyl$3,071$14,27220 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in El Paso

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →